Health Care M&A Deals, July 31, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is a global development and commercialization agreement for DS-1062 between AstraZeneca plc and Daiichi Sankyo Company valued at $1 billion. DS-1062 is Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), and potential new medicine for the treatment of multiple tumor types. The companies will... Read More »
Health Care M&A Deals, July 24, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was Dedalus Group’s acquisition of DXC’s healthcare software provider business for $525 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service alerts you to... Read More »
Health Care M&A Deals, July 17, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was Genentech, Inc.’s collaboration on pralsetinib with Blueprint Medicines Corporation valued at $775 million. Blueprint Medicines and Genentech will co-commercialize pralsetinib and equally share profits in the U.S. Roche will obtain an exclusive license to commercialize pralsetinib outside the U.S., excluding Greater China. To subscribe to our... Read More »
Second Quarter Healthcare M&A Activity Drops
The decline in second quarter healthcare M&A probably won’t surprise many of our readers. The second quarter was the first full quarter of healthcare M&A in the shadow of the COVID-19 pandemic, and deal making took a hit as a result, as shown in results from our DSO database. Compared with Q1:20, Q2:20 dropped 20%, with 322 transactions on the books. Compared with Q2:19 (486 transactions), deal volume in Q2:20 declined even further at 34%. Source: Health Care M&A, July 2020 Long-Term Care and Physician Medical Groups were among the hardest hit sectors, declining 40% and 50% in activity compared with Q1:20, respectively. Year-over-year, the difference is starker. Long-Term... Read More »
Health Care M&A Deals, July 10, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week based on announced prices was Primovie’s acquisition of eight senior care facilities for $164.4 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service alerts you to... Read More »